104 related articles for article (PubMed ID: 10081868)
1. The changing pattern of prostate cancer at the time of diagnosis: characteristics of screen detected prostate cancer in a population based screening study.
Rietbergen JB; Hoedemaeker RF; Kruger AE; Kirkels WJ; Schröder FH
J Urol; 1999 Apr; 161(4):1192-8. PubMed ID: 10081868
[TBL] [Abstract][Full Text] [Related]
2. Prostate cancer detection at low prostate specific antigen.
Schröder FH; van der Cruijsen-Koeter I; de Koning HJ; Vis AN; Hoedemaeker RF; Kranse R
J Urol; 2000 Mar; 163(3):806-12. PubMed ID: 10687982
[TBL] [Abstract][Full Text] [Related]
3. Characteristics of screening detected prostate cancer in men 50 to 66 years old with 3 to 4 ng./ml. Prostate specific antigen.
Lodding P; Aus G; Bergdahl S; Frösing R; Lilja H; Pihl CG; Hugosson J
J Urol; 1998 Mar; 159(3):899-903. PubMed ID: 9474178
[TBL] [Abstract][Full Text] [Related]
4. Early diagnosis of prostate cancer in the Western Cape.
Heyns CF; Naudé AM; Visser AJ; Marais DC; Stopforth HB; Nyarko JK; Stellmacher GA
S Afr Med J; 2001 Aug; 91(8):679-84. PubMed ID: 11584784
[TBL] [Abstract][Full Text] [Related]
5. Screening of prostate cancer. Is it needed? Russian experience.
Matveev VB
Arch Ital Urol Androl; 2006 Dec; 78(4):149-51. PubMed ID: 17269620
[TBL] [Abstract][Full Text] [Related]
6. Screening for prostate cancer.
Pode D; Shapiro A; Lebensart P; Meretyk S; Katz G; Barak V
Isr J Med Sci; 1995; 31(2-3):125-8. PubMed ID: 7538101
[TBL] [Abstract][Full Text] [Related]
7. The risks of prostate cancer detection by transrectal ultrasound guide biopsy in Thai men with abnormal prostatic-specific antigen or abnormal digital rectal examination.
Leewansangtong S; Tantiwong A; Ratanarapee S; Nualyong C; Soontrapa S
J Med Assoc Thai; 2000 Dec; 83(12):1519-24. PubMed ID: 11253893
[TBL] [Abstract][Full Text] [Related]
8. Prostate cancer screening within a prostate specific antigen range of 3 to 3.9 ng./ml.: a comparison of digital rectal examination and free prostate specific antigen as supplemental screening tests.
Mäkinen T; Tammela TL; Hakama M; Stenman UH; Rannikko S; Aro J; Juusela H; Määttänen L; Auvinen A
J Urol; 2001 Oct; 166(4):1339-42. PubMed ID: 11547069
[TBL] [Abstract][Full Text] [Related]
9. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer.
Catalona WJ; Smith DS; Ratliff TL; Dodds KM; Coplen DE; Yuan JJ; Petros JA; Andriole GL
N Engl J Med; 1991 Apr; 324(17):1156-61. PubMed ID: 1707140
[TBL] [Abstract][Full Text] [Related]
10. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements.
Catalona WJ; Smith DS; Ornstein DK
JAMA; 1997 May; 277(18):1452-5. PubMed ID: 9145717
[TBL] [Abstract][Full Text] [Related]
11. Patients with abnormal ultrasound of the prostate but normal digital rectal examination should be classified as having clinical stage T2 tumors.
Tiguert R; Gheiler EL; Grignon DJ; Littrup PJ; Sakr W; Pontes JE; Wood DP
J Urol; 2000 May; 163(5):1486-90. PubMed ID: 10751863
[TBL] [Abstract][Full Text] [Related]
12. The free-to-total prostate specific antigen ratio improves the specificity of prostate specific antigen in screening for prostate cancer in the general population.
Bangma CH; Rietbergen JB; Kranse R; Blijenberg BG; Petterson K; Schröder FH
J Urol; 1997 Jun; 157(6):2191-6. PubMed ID: 9146612
[TBL] [Abstract][Full Text] [Related]
13. Mass screening of 12,027 elderly men for prostate carcinoma by measuring serum prostate specific antigen.
Zhang HF; Wang HL; Xu N; Li SW; Ji GY; Li XM; Pan YZ; Zhang L; Zhao XJ; Gao HW
Chin Med J (Engl); 2004 Jan; 117(1):67-70. PubMed ID: 14733776
[TBL] [Abstract][Full Text] [Related]
14. Prostate specific antigen based biennial screening is sufficient to detect almost all prostate cancers while still curable.
Hugosson J; Aus G; Lilja H; Lodding P; Pihl CG; Pileblad E
J Urol; 2003 May; 169(5):1720-3. PubMed ID: 12686817
[TBL] [Abstract][Full Text] [Related]
15. Population-based screening for prostate cancer by measuring total serum prostate-specific antigen in Iran.
Hosseini SY; Moharramzadeh M; Ghadian AR; Hooshyar H; Lashay AR; Safarinejad MR
Int J Urol; 2007 May; 14(5):406-11. PubMed ID: 17511722
[TBL] [Abstract][Full Text] [Related]
16. Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop?
Djavan B; Ravery V; Zlotta A; Dobronski P; Dobrovits M; Fakhari M; Seitz C; Susani M; Borkowski A; Boccon-Gibod L; Schulman CC; Marberger M
J Urol; 2001 Nov; 166(5):1679-83. PubMed ID: 11586201
[TBL] [Abstract][Full Text] [Related]
17. [Diagnosis of localized prostate cancer: screening and preoperative staging].
Hammerer P; Huland H
Urologe A; 1991 Nov; 30(6):378-86. PubMed ID: 1722921
[TBL] [Abstract][Full Text] [Related]
18. [An experience of individual and early diagnosis of prostate cancer in a Tunisian centre].
Khouaja K; Ben Sorba N; Bouslama A; Youssef A; Taher Mosbah A
Prog Urol; 2005 Apr; 15(2):255-9. PubMed ID: 15999603
[TBL] [Abstract][Full Text] [Related]
19. Update of the results of the Spanish branch of the European Randomized Study on Screening for Prostate Cancer (ERSPC).
Luján M; Páez Á; Angulo JC; Andrés G; Gimbernat H; Redondo C; Torres GM; Berenguer A
Actas Urol Esp; 2015 Sep; 39(7):405-13. PubMed ID: 25777669
[TBL] [Abstract][Full Text] [Related]
20. Pathological features of prostate cancer detected on initial and repeat prostate biopsy: results of the prospective European Prostate Cancer Detection study.
Djavan B; Mazal P; Zlotta A; Wammack R; Ravery V; Remzi M; Susani M; Borkowski A; Hruby S; Boccon-Gibod L; Schulman CC; Marberger M
Prostate; 2001 May; 47(2):111-7. PubMed ID: 11340633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
